Travere Therapeutics Stock In The News
| TVTX Stock | USD 20.83 0.13 0.63% |
Our overall analysis of Travere Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Travere Therapeutics. The specific impact of Travere Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Travere Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Travere Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Travere Therapeutics Backtesting and Travere Therapeutics Hype Analysis. For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Travere and other traded companies coverage with news coverage. We help investors stay connected with Travere headlines for the 20th of March to make an informed investment decision based on correlating the impacts of news items on Travere Stock performance. Please note that trading solely based on the Travere Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Travere |
Travere Therapeutics Today Top News and Investor Outlook
Travere Therapeutics Past News Timeline
Travere Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Travere earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Travere Therapeutics that are available to investors today. That information is available publicly through Travere media outlets and privately through word of mouth or via Travere internal channels. However, regardless of the origin, that massive amount of Travere data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Travere Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Travere Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Travere Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Travere Therapeutics alpha.
Travere Largest EPS Surprises
Earnings surprises can significantly impact Travere Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-05-04 | 2017-03-31 | -0.26 | -0.29 | -0.03 | 11 | ||
2017-03-01 | 2016-12-31 | -0.26 | -0.23 | 0.03 | 11 | ||
2020-11-05 | 2020-09-30 | -0.52 | -0.44 | 0.08 | 15 | ||
2025-02-13 | 2024-12-31 | -0.3786 | -0.47 | -0.0914 | 24 | ||
2017-08-09 | 2017-06-30 | -0.21 | -0.34 | -0.13 | 61 | ||
2016-08-04 | 2016-06-30 | -0.23 | -0.37 | -0.14 | 60 |
Travere Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Travere Therapeutics Stock. Current markets are slightly bearish. About 58% of major world exchanges and indexes are down. See today's market update for more information.
12th of March 2025
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 at finance.yahoo.com
3rd of March 2025
Disposition of 8951 shares by Elizabeth Reed of Travere Therapeutics at 19.78 subject to R... at MacroaxisInsider
27th of February 2025
Travere Therapeutics Price Target Raised to 35.00 at Citigroup - MarketBeat at news.google.com
24th of February 2025
Citigroup Boosts Travere Therapeutics Price Target to 35.00 at thelincolnianonline.com
21st of February 2025
Travere Therapeutics Inc Q4 2024 Earnings Call Highlights Strong Phil Spari Sales and ... at gurufocus.com
20th of February 2025
Travere Therapeutics Reports Q4 Loss, Tops Revenue Estimates at zacks.com
13th of February 2025
Travere Therapeutics Inc Announces Upcoming Financial Results Release at gurufocus.com
5th of February 2025
Travere Therapeutics, Inc. CEO Eric M. Dube Sells 50,691 Shares of Stock at thelincolnianonline.com
13th of January 2025
Pacira Soars 11.1 percent Is Further Upside Left in the Stock at zacks.com
Travere Therapeutics Investors Sentiment
The influence of Travere Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Travere. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Travere Therapeutics' public news can be used to forecast risks associated with an investment in Travere. The trend in average sentiment can be used to explain how an investor holding Travere can time the market purely based on public headlines and social activities around Travere Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Travere Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Travere Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Travere Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Travere Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Travere Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Travere Therapeutics' short interest history, or implied volatility extrapolated from Travere Therapeutics options trading.
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.